ClinicalTrials.gg
CompletedNCT01477333Updated Dec 27, 2023Results posted

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

A Phase 2 interventional study of UT-15C SR and Tyvaso Inhalation Solution in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
30th of 44
18 · median 32
Started
2011
the only one that year
Phase 2
7 of 44
1 open now
Registered
19th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 30th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 19th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The purpose of this multi-center, open-label, safety and tolerability study was to assess the addition of oral treprostinil (UT-15C sustained release [SR] tablets) to subjects currently receiving Tyvaso (treprostinil) inhalation solution. During the 24-week evaluation period, the study evaluated the changes in the following assessments: hemodynamics, 6-minute walk test (6MWT), Borg dyspnea score, N-Terminal pro-brain natriuretic peptide (NT-proBNP), World Health Organization (WHO) Functional Class, and safety assessments.

Eligible subjects had a diagnosis of pulmonary arterial hypertension (PAH), currently were receiving Tyvaso, and may have been receiving other approved PAH specific oral therapies (endothelin receptor antagonists [ERAs] and/or phosphodiesterase type 5 inhibitor [PDE5-I], if at a stable dose for ≥30 days). At Baseline, subjects received the first dose of 0.125 mg UT-15C SR.

Read the detailed description

This was a multi-center, open-label, safety and tolerability study in WHO Group 1 PAH subjects adding UT-15C SR to Tyvaso and PAH approved background therapy. This study had a 24-week evaluation period followed by a long term safety period. Six study visits occurred in the first 24 weeks of study; Screening, Baseline, Week 4, Week 8, Week 12, and Week 24 visits. Right heart catheterization occurred between 2-4 hours following the last Tyvaso dose at Baseline (prior to the administration of UT-15C SR) and Week 24.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Tyvaso
  • UT-15C SR
  • PAH
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Significant inclusion criteria included:

  1. Subjects were between 18 to 75 years of age
  2. Diagnosis of PAH: Idiopathic; Heritable; Associated with: Collagen vascular disease, (HIV) infection, appetite suppressant or toxin use, or repaired congenital systemic-to-pulmonary shunts (repaired ≥5 years)
  3. Had been receiving Tyvaso for at least 4 weeks (≥9 breaths, 4 times a day [QID]) and required additional therapy
  4. In addition to Tyvaso, subjects may have been receiving other approved PAH specific oral therapies (ERAs and/or PDE-5 inhibitors, if at a stable dose)

Significant exclusion criteria included:

  1. The subject was pregnant or lactating
  2. The subject had previously received UT-15C SR
  3. The subject had added, discontinued or changed the dosing regimen (i.e., prescription) of conventional PAH therapies (e.g., oral vasodilators, oxygen, digoxin) within 21 days of Baseline
  4. The subject was receiving a FDA approved PAH therapy (e.g., ERA and/or PDE-5 inhibitor) for less than 30 days prior to Baseline, or the dose had been modified within 30 days of Baseline
  5. The subject had any disease associated with PAH other than collagen vascular disease, HIV infection, repaired congenital systemic-to-pulmonary shunts (for at least 5 years), or appetite suppressant/toxin use (e.g., portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, etc.), or had an atrial septostomy
  6. The subject had ischemic heart disease prior to Screening, or left ventricular dysfunction as evidenced by a mean PCWP (or a left ventricular end diastolic pressure) greater than 15 mmHg or (LVEF) less than 40% as assessed by either multigated angiogram (MUGA), angiography or echocardiography. Patients with abnormal left ventricular function attributable entirely to impaired left ventricular filling due to the effects of right ventricular overload were not excluded.
  7. The subject had uncontrolled systemic hypertension as evidenced by systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg at Baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    UT-15C SR BID

    Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.

    Drug: UT-15C SR · Drug: Tyvaso Inhalation Solution

Interventions

  • Initiated at 0.125 mg BID, titrated as clinically indicated.

    Also known as: treprostinil diethanolamine, sustained release

  • Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline

    Also known as: Treprostinil

06

What researchers measure

Primary outcomes

  1. Change in Hemodynamic Parameters From Baseline to Week 24.

    Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: mean pulmonary arterial pressure (PAPm), mean systemic arterial pressure (SAPm), mean right atrial pressure (RAPm), and mean pulmonary capillary wedge pressure (PCWPm).

    Time frame: Baseline and Week 24

  2. Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.

    Heart rate was assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.

    Time frame: Baseline and Week 24

  3. Change in Hemodynamic Parameters (Arterial and Venous Oxygen Saturation) From Baseline to Week 24.

    Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included arterial oxygen saturation (SaO2) and mixed venous oxygen saturation (SvO2).

    Time frame: Baseline and Week 24

  4. Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.

    Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.

    Time frame: Baseline and Week 24

  5. Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.

    Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included cardiac index (CI).

    Time frame: Baseline and Week 24

  6. Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.

    Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: pulmonary vascular resistance index (PVRI).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Over the 24-week Treatment Period.

    The 6MWT was conducted at Baseline, 2 to 4 hours after the last Tyvaso dose, and prior to first dose of UT-15C SR. The 6MWT was also performed at Weeks 4, 12, and 24, or at the time of premature termination of study drug if prior to the Week 24 visit.

    Time frame: Baseline and Weeks 4, 12, and 24

  2. Time to Clinical Worsening Over the Treatment Period.

    Clinical worsening was assessed continuously from Baseline through each subject's last study visit. Clinical worsening was defined as the occurrence of any one or more of the following: death (all causes), hospitalization as a result of worsening pulmonary arterial hypertension (PAH), and initiation of a parenteral prostacyclin.

    Time frame: Clinical worsening was assessed continuously from Baseline through each subject's last study visit

  3. Shift From Baseline in World Health Organization (WHO) Functional Class Over the 24-week Treatment Period.

    The WHO functional classification for pulmonary hypertension was assessed at Baseline prior to starting UT-15C SR, Weeks 4, 8, 12, and 24, or at the time of premature termination if prior to Week 24. The WHO functional classification ranges from I (patient's disease does not affect daily activities) to IV (patient's disease causes severe impairment).

    Time frame: Baseline and Weeks 4, 8, 12, and 24

  4. N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Over the 24-week Treatment Period.

    NT-proBNP was assessed at Baseline prior to starting UT-15C SR, Weeks 12 and 24, or at the time of premature termination if prior to Week 24. Blood for NT-proBNP assessment was collected before the 6MWT was conducted.

    Time frame: Baseline and Weeks 12 and 24

07

Results

Posted Mar 6, 2017

Participant flow

The recruitment period for this study was October 2011 to November 2013.

Participant flow — Overall Study
MilestoneUT-15C SR BID
Started18
Completed15
Not completed3
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Clinical deterioration1

Outcome measures

PrimaryChange in Hemodynamic Parameters From Baseline to Week 24.

Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: mean pulmonary arterial pressure (PAPm), mean systemic arterial pressure (SAPm), mean right atrial pressure (RAPm), and mean pulmonary capillary wedge pressure (PCWPm).

Time frame:
Baseline and Week 24
Reported as:
Median · mmHg
Change in Hemodynamic Parameters From Baseline to Week 24.
mmHgUT-15C SR BID
Systolic systemic arterial pressure (mmHg)-2.0 (-22 to 21)
Diastolic systemic arterial pressure (mmHg)0 (-20 to 18)
Mean systemic arterial pressure (mmHg)-1.0 (-29 to 18)
Systolic pulmonary arterial pressure (mmHg)3.0 (-51 to 12)
Diastolic pulmonary arterial pressure (mmHg)0 (-16 to 10)
Mean pulmonary arterial pressure (mmHg)0 (-26 to 10)
Mean right atrial pressure (mmHg)0 (-9 to 6)
Mean pulmonary capillary wedge pressure (mmHg)-1.0 (-15 to 8)
SecondaryChange in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Over the 24-week Treatment Period.

The 6MWT was conducted at Baseline, 2 to 4 hours after the last Tyvaso dose, and prior to first dose of UT-15C SR. The 6MWT was also performed at Weeks 4, 12, and 24, or at the time of premature termination of study drug if prior to the Week 24 visit.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Median · Meters
Change in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Over the 24-week Treatment Period.
MetersUT-15C SR BID
Week 420.5 (-111 to 119)
Week 1212.4 (-70 to 101)
Week 2414.9 (-178 to 101)
SecondaryTime to Clinical Worsening Over the Treatment Period.

Clinical worsening was assessed continuously from Baseline through each subject's last study visit. Clinical worsening was defined as the occurrence of any one or more of the following: death (all causes), hospitalization as a result of worsening pulmonary arterial hypertension (PAH), and initiation of a parenteral prostacyclin.

Time frame:
Clinical worsening was assessed continuously from Baseline through each subject's last study visit
Reported as:
Mean · Days
Time to Clinical Worsening Over the Treatment Period.
DaysUT-15C SR BID
Time to Clinical Worsening Over the Treatment Period.234 ± 200.3
SecondaryShift From Baseline in World Health Organization (WHO) Functional Class Over the 24-week Treatment Period.

The WHO functional classification for pulmonary hypertension was assessed at Baseline prior to starting UT-15C SR, Weeks 4, 8, 12, and 24, or at the time of premature termination if prior to Week 24. The WHO functional classification ranges from I (patient's disease does not affect daily activities) to IV (patient's disease causes severe impairment).

Time frame:
Baseline and Weeks 4, 8, 12, and 24
Reported as:
Number · participants
Shift From Baseline in World Health Organization (WHO) Functional Class Over the 24-week Treatment Period.
participantsClass II to Class IIClass II to Class IIIClass III to Class IIClass III to Class III
Week 48109
Week 86327
Week 129018
Week 247125
SecondaryN-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Over the 24-week Treatment Period.

NT-proBNP was assessed at Baseline prior to starting UT-15C SR, Weeks 12 and 24, or at the time of premature termination if prior to Week 24. Blood for NT-proBNP assessment was collected before the 6MWT was conducted.

Time frame:
Baseline and Weeks 12 and 24
Reported as:
Mean · pg/mL
N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Over the 24-week Treatment Period.
pg/mLUT-15C SR BID
Week 12-99 ± 295
Week 24144 ± 464
PrimaryChange in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.

Heart rate was assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.

Time frame:
Baseline and Week 24
Reported as:
Median · beats/min
Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.
beats/minUT-15C SR BID
Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.4.00 (-29.0 to 25.0)
PrimaryChange in Hemodynamic Parameters (Arterial and Venous Oxygen Saturation) From Baseline to Week 24.

Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included arterial oxygen saturation (SaO2) and mixed venous oxygen saturation (SvO2).

Time frame:
Baseline and Week 24
Reported as:
Median · percentage bound to hemoglobin
Change in Hemodynamic Parameters (Arterial and Venous Oxygen Saturation) From Baseline to Week 24.
percentage bound to hemoglobinUT-15C SR BID
Arterial oxygen saturation (%)1.0 (-5 to 5)
Mixed venous oxygen saturation (%)0 (-9 to 4)
PrimaryChange in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.

Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.

Time frame:
Baseline and Week 24
Reported as:
Median · L/min
Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.
L/minUT-15C SR BID
Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.0 (-1 to 4)
PrimaryChange in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.

Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included cardiac index (CI).

Time frame:
Baseline and Week 24
Reported as:
Median · L/min/m^2
Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.
L/min/m^2UT-15C SR BID
Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.0 (0 to 1)
PrimaryChange in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.

Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: pulmonary vascular resistance index (PVRI).

Time frame:
Baseline and Week 24
Reported as:
Median · dyn*s/cm^5*m^2
Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.
dyn*s/cm^5*m^2UT-15C SR BID
Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.0.2 (-10 to 7)

Adverse events

Collected over Adverse events were recorded throughout the 24-week study, including the screening phase, as well as during the long-term follow-up period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UT-15C SR BID—2/18 (11.1%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventUT-15C SR BID
AscitesGastrointestinal disorders1/18
DiarrheaGastrointestinal disorders1/18
Fluid overloadMetabolism and nutrition disorders1/18
HyponatremiaMetabolism and nutrition disorders1/18
Renal failure acuteRenal and urinary disorders1/18
MalnutritionMetabolism and nutrition disorders1/18
Most frequent other events
Showing 10 of 84
Most frequent other events
EventUT-15C SR BID
HeadacheNervous system disorders14/18
NauseaGastrointestinal disorders12/18
DiarrheaGastrointestinal disorders11/18
FlushingVascular disorders8/18
FatigueGeneral disorders6/18
DyspneaRespiratory, thoracic and mediastinal disorders5/18
CoughRespiratory, thoracic and mediastinal disorders4/18
Edema peripheralGeneral disorders4/18
Pain in extremityMusculoskeletal and connective tissue disorders4/18
Abdominal painGastrointestinal disorders3/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)UT-15C SR BID
<=18 years0
Between 18 and 65 years14
>=65 years4
Age, Continuous
Age, Continuous(years)UT-15C SR BID
Mean51.3 (20 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)UT-15C SR BID
Female13
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UT-15C SR BID
Hispanic or Latino2
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UT-15C SR BID
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)UT-15C SR BID
United States18
08

Study locations

6 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2011
First posted
Nov 22, 2011
Start
Oct 2011
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Mar 6, 2017
Last update
Dec 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01477333
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Oct 2011
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Mar 6, 2017
Last update
Dec 27, 2023

Study contacts

Cynthia Madden, MD, MPH
study chair · Associate Director, Medical Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion